Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) has announced that chief financial officer Hans-Peter Rudolf is stepping down from his position to pursue other opportunities.
Paul Spoors, group company controller since 2019, will take on additional responsibilities and report to chief executive Greg Madison, whilst an executive search firm identifies a replacement chief financial officer.
Rudolf is slated to leave on 20 October and will remain available to the company until the end of the month.
Shield noted that his resignation is not the result of any dispute or disagreement with Shield on any matters relating to Shield's financial statements, internal controls, operations, policies or practices.
"I would like to thank the board and the senior management team for their support during my time as CFO,” Rudolf said in a statement.
“I have every confidence in the future success of the business and, as a shareholder, I wish the team the very best of continued success for the future."
Chief executive Greg Madison, meanwhile, added: "On behalf of the board, I would like to thank Hans-Peter for his leadership and contributions to the business and our efforts to transform Shield into a fast growing commercial specialty pharmaceutical company with a completely-built-out U.S. commercial team.
“He has built a strong accounting and finance team that will provide a solid foundation for growth. We wish him every success in the future."